Yang H - Search Results

1

Health care resource utilization and cost burden of hemophilia B in the United States.

Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N. Buckner TW, et al. Among authors: yang h. Blood Adv. 2021 Apr 13;5(7):1954-1962. doi: 10.1182/bloodadvances.2020003424. Blood Adv. 2021. PMID: 33830206 Free PMC article.

2

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.

Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Yu AP, et al. Among authors: yang h. J Med Econ. 2011;14(3):315-23. doi: 10.3111/13696998.2011.576295. Epub 2011 Apr 18. J Med Econ. 2011. PMID: 21500975 Free article.

3

Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.

Yang H, Yu AP, Wu EQ, Yim YM, Yu E. Yang H, et al. J Med Econ. 2011;14(5):542-52. doi: 10.3111/13696998.2011.596600. Epub 2011 Jul 6. J Med Econ. 2011. PMID: 21728912 Free article.

4

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.

Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Bron M, et al. Among authors: yang h. Postgrad Med. 2012 Jan;124(1):124-32. doi: 10.3810/pgm.2012.01.2525. Postgrad Med. 2012. PMID: 22314122

5

Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.

Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ. Kim Le T, et al. Among authors: yang h. J Med Econ. 2012;15(4):786-95. doi: 10.3111/13696998.2012.682632. Epub 2012 Apr 20. J Med Econ. 2012. PMID: 22475042 Free article.

6

Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.

Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ. Erder MH, et al. Among authors: yang h. J Med Econ. 2012;15(6):1078-87. doi: 10.3111/13696998.2012.689270. Epub 2012 Jun 14. J Med Econ. 2012. PMID: 22537226 Free article.

7

Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.

Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Xie J, et al. Among authors: yang h. J Med Econ. 2013;16(2):278-88. doi: 10.3111/13696998.2012.749788. Epub 2012 Dec 5. J Med Econ. 2013. PMID: 23153318 Free article.

8

Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.

Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL. Yang H, et al. Appl Health Econ Health Policy. 2014 Feb;12(1):85-93. doi: 10.1007/s40258-013-0072-7. Appl Health Econ Health Policy. 2014. PMID: 24385260

9

Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.

Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C. Fuldeore M, et al. Among authors: yang h. Fertil Steril. 2015 Jan;103(1):163-71. doi: 10.1016/j.fertnstert.2014.10.011. Epub 2014 Nov 15. Fertil Steril. 2015. PMID: 25455535 Free article.

10

The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.

Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V. Macalalad AR, et al. Among authors: yang h. Curr Med Res Opin. 2015 Mar;31(3):537-45. doi: 10.1185/03007995.2015.1008131. Epub 2015 Feb 9. Curr Med Res Opin. 2015. PMID: 25598441 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61,568 results

Search Page

Filters